Trishna Goswami
Chief Tech/Sci/R&D Officer at IN8BIO, INC.
Net worth: 7 940 $ as of 2024-03-30
Profile
Trishna Goswami is currently the Chief Medical Officer at IN8bio, Inc. Prior to this, she was the Vice President of Clinical Development at Immunomedics, Inc. from 2018 to 2021.
She also worked as the Senior Director of Medical at Stemline Therapeutics, Inc. from 2017 to 2018.
Dr. Goswami's education includes an MBA from Robert H.
Smith School of Business and a doctorate from Drexel University College of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IN8BIO, INC.
0.02% | 2024-02-06 | 6,729 ( 0.02% ) | 7 940 $ | 2024-03-30 |
Trishna Goswami active positions
| Companies | Position | Start |
|---|---|---|
| IN8BIO, INC. | Chief Tech/Sci/R&D Officer | 2021-11-15 |
Former positions of Trishna Goswami
| Companies | Position | End |
|---|---|---|
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 2021-11-30 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-05-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Training of Trishna Goswami
| Robert H. Smith School of Business | Masters Business Admin |
| Drexel University College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Trishna Goswami
